Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease

European Journal of Medicinal Chemistry

Volumn 108, Issue , 2016, Pages 687-700

  Lemes, Laís Flávia Nunes ^a,b   De Andrade Ramos, Giselle ^a,b   De Oliveira, Andressa Souza ^a,b   Da Silva, Fernanda Motta R ^c   De Castro Couto, Gina ^c   Da Silva Boni, Marina ^c   Guimarães, Marcos Jorge R ^c   Souza, Isis Nem O ^c   Bartolini, Manuela ^d   Andrisano, Vincenza ^d   Do Nascimento Nogueira, Patrícia Coelho ^e   Silveira, Edilberto Rocha ^e   Brand, Guilherme D ^a   Soukup, Ondřej ^f,g   Korábečný, Jan ^f,g   Romeiro, Nelilma C ^c   Castro, Newton G ^c   Bolognesi, Maria Laura ^d   Romeiro, Luiz Antonio Soares ^a,b  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^f UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^g NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Cashew nut shell liquid; Dual binding site AChE inhibitors; Multitarget compounds

Indexed keywords

1 (2 METHOXYPHENYL) 4 [8 (3 METHOXYPHENYL)OCTYL]PIPERAZINE; 1 (8 BROMOOCTYL) 3 METHOXYBENZENE; 1 [8 (3 METHOXIPHENYL)OCTYL]PYRROLIDINE; 1 [8 (3 METHOXYPHENYL)OCTYL] 4 ACETYLPIPERAZINE; 1 [8 (3 METHOXYPHENYL)OCTYL] 4 CARBO 1,1 DIMETHYLETHOXYPIPERAZINE; 1 [8 (3 METHOXYPHENYL)OCTYL] 4 METHYLPIPERAZINE; 1 [8 (3 METHOXYPHENYL)OCTYL] 4 PHENYLPIPERAZINE; 1 [8 (3 METHOXYPHENYL)OCTYL]PIPERIDIN 3 OL; 1 [8 (3 METHOXYPHENYL)OCTYL]PIPERIDIN 3 YL ACETATE; 1 [8 (3 METHOXYPHENYL)OCTYL]PIPERIDIN 3 YL DIMETHYLCARBAMATE; 1 [8 (3 METHOXYPHENYL)OCTYL]PIPERIDIN 4 OL; 1 [8 (3 METHOXYPHENYL)OCTYL]PIPERIDIN 4 YL ACETATE; 1 [8 (3 METHOXYPHENYL)OCTYL]PIPERIDIN 4 YL DIMETHYLCARBAMATE; 1 [8 (3 METHOXYPHENYL)OCTYL]PIPERIDINE; 1 [8 (3 METHOXYPHENYL)OCTYL]PIRROLIDIN 3 YL ACETATE; 1 [8 (3 METHOXYPHENYL)OCTYL]PYRROLIDIN 3 OL; 1 [8 (3 METHOXYPHENYL)OCTYL]PYRROLIDIN 3 OL DIMETHYLCARBAMATE; 3 METHOXYPHENYLOCTANOL; 4 [8 (3 METHOXYPHENYL)OCTYL]MORPHOLINE; 4 [8 (3 METHOXYPHENYL)OCTYL]THIOMORPHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; N (2 METHOXYBENZYL) 8 (3 METHOXYPHENYL)OCTAN 1 AMINE; N BENZYL N ETHYL 8 (3 METHOXYPHENYL)OCTAN 1 AMINE; N ETHYL N (2 METHOXYBENZYL) 8 (3 METHOXYPHENYL)OCTAN 1 AMINE; PLANT EXTRACT; RIVASTIGMINE; UNCLASSIFIED DRUG; [1 [8 (3 METHOXYPHENYL)OCTYL]PIPERIDIN 2 YL]METHYL DIMETHYLCARBAMATE; CARDANOL; CHOLINESTERASE; PHENOL DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; BINDING SITE; BLOOD BRAIN BARRIER; CASHEW NUT; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; DRUG DESIGN; DRUG PENETRATION; ENZYME ACTIVITY; HT 29 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MOLECULAR MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; HT-29 CELL LINE; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ALZHEIMER DISEASE; BINDING SITES; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HT29 CELLS; HUMANS; MOLECULAR STRUCTURE; PHENOLS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84952673708     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.12.024     Document Type: Article

References (50)

1. J.L. Cummings, T. Morstorf, and K. Zhong Alzheimer's disease drug-development pipeline: few candidates, frequent failures Alzheimers Res. Ther. 6 2014 37
2. World Alzheimer Report The Global Impact of Dementia 2015 Alzheimer's Disease International
3. A. Kumar, A. Singh, and Ekavali A review on Alzheimer's disease pathophysiology and its management: an update Pharmacol. Rep. 67 2015 195 203
4. L.S. Schneider, F. Mangialasche, N. Andreasen, H. Feldman, E. Giacobini, R. Jones, V. Mantua, P. Mecocci, L. Pani, B. Winblad, and M. Kivipelto Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 J. Intern. Med. 275 2014 251 283
5. D.J. Triggle Pharmaceuticals in Society Green and Sustainable Pharmacy 2010 Springer 23 35
6. J. Julis, S.A. Bartlett, S. Baader, N. Beresford, E.J. Routledge, C.S.J. Cazin, and D.J. Cole-Hamilton Selective ethenolysis and oestrogenicity of compounds from cashew nut shell liquid Green Chem. 16 2014 2846 2856
7. C.S.K. Lin, L.A. Pfaltzgraff, L. Herrero-Davila, E.B. Mubofu, S. Abderrahim, J.H. Clark, A.A. Koutinas, N. Kopsahelis, K. Stamatelatou, and F. Dickson Food waste as a valuable resource for the production of chemicals, materials and fuels. Current situation and global perspective Energy Environ. Sci. 6 2013 426 464
8. F.B. Hamad, and E.B. Mubofu Potential biological applications of bio-based anacardic acids and their derivatives Int. J. Mol. Sci. 16 2015 8569 8590
9. M. Hemshekhar, M. Sebastin Santhosh, K. Kemparaju, and K.S. Girish Emerging roles of anacardic acid and its derivatives: a pharmacological overview Basic Clin. Pharmacol. Toxicol. 110 2011 122 132
10. A.A. de Paula, J.B. Martins, M.L. dos Santos, L.C. Nascente, L.A. Romeiro, T.F. Areas, K.S. Vieira, N.F. Gamboa, N.G. Castro, and R. Gargano New potential AChE inhibitor candidates Eur. J. Med. Chem. 44 2009 3754 3759
11. P.S. Portoghese From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes J. Med. Chem. 44 2001 2259 2269
12. D. Munoz-Torrero, and P. Camps Dimeric and hybrid anti-Alzheimer drug candidates Curr. Med. Chem. 13 2006 399 422
13. H. Haviv, D.M. Wong, I. Silman, and J.L. Sussman Bivalent ligands derived from Huperzine A as acetylcholinesterase inhibitors Curr. Top. Med. Chem. 7 2007 375 387
14. S. Thiratmatrakul, C. Yenjai, P. Waiwut, O. Vajragupta, P. Reubroycharoen, M. Tohda, and C. Boonyarat Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease Eur. J. Med. Chem. 75 2014 21 30
15. J. Korabecny, R. Dolezal, P. Cabelova, A. Horova, E. Hruba, J. Ricny, L. Sedlacek, E. Nepovimova, K. Spilovska, M. Andrs, K. Musilek, V. Opletalova, V. Sepsova, D. Ripova, and K. Kuca 7-MEOTA-donepezil like compounds as cholinesterase inhibitors: synthesis, pharmacological evaluation, molecular modeling and QSAR studies Eur. J. Med. Chem. 82 2014 426 438
16. O. Di Pietro, E. Viayna, E. Vicente-Garcia, M. Bartolini, R. Ramon, J. Juarez-Jimenez, M.V. Clos, B. Perez, V. Andrisano, F.J. Luque, R. Lavilla, and D. Munoz-Torrero 1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies Eur. J. Med. Chem. 73 2014 141 152
17. Y.P. Pang, P. Quiram, T. Jelacic, F. Hong, and S. Brimijoin Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease J. Biol. Chem. 271 1996 23646 23649
18. M.L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti, and C. Melchiorre From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease Mini Rev. Med. Chem. 8 2008 960 967
19. A. Rampa, F. Belluti, S. Gobbi, and A. Bisi Hybrid-based multi-target ligands for the treatment of Alzheimer's disease Curr. Top. Med. Chem. 11 2011 2716 2730
20. H.F. Ji, and H.Y. Zhang Multipotent natural agents to combat Alzheimer's disease. Functional spectrum and structural features Acta Pharmacol. Sin. 29 2008 143 151
21. M. Stefani, and S. Rigacci Protein folding and aggregation into amyloid: the interference by natural phenolic compounds Int. J. Mol. Sci. 14 2013 12411 12457
22. M. Rosini, E. Simoni, M. Bartolini, A. Tarozzi, R. Matera, A. Milelli, P. Hrelia, V. Andrisano, M.L. Bolognesi, and C. Melchiorre Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease Eur. J. Med. Chem. 46 2011 5435 5442
23. M.L. Bolognesi, M. Bartolini, A. Tarozzi, F. Morroni, F. Lizzi, A. Milelli, A. Minarini, M. Rosini, P. Hrelia, V. Andrisano, and C. Melchiorre Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity Bioorg. Med. Chem. Lett. 21 2011 2655 2658
24. C. Melchiorre, M.L. Bolognesi, A. Minarini, M. Rosini, and V. Tumiatti Polyamines in drug discovery: from the universal template approach to the multitarget-directed ligand design strategy J. Med. Chem. 53 2010 5906 5914
25. Y. Bourne, J. Grassi, P.E. Bougis, and P. Marchot Conformational flexibility of the acetylcholinesterase tetramer suggested by x-ray crystallography J. Biol. Chem. 274 1999 30370 30376
26. M. Khoobi, M. Alipour, A. Sakhteman, H. Nadri, A. Moradi, M. Ghandi, S. Emami, A. Foroumadi, and A. Shafiee Design, synthesis, biological evaluation and docking study of 5-oxo-4,5-dihydropyrano[3,2-c]chromene derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors Eur. J. Med. Chem. 68 2013 260 269
27. H. Pajouhesh, and G.R. Lenz Medicinal chemical properties of successful central nervous system drugs NeuroRx 2 2005 541 553
28. D.E. Clark In silico prediction of blood-brain barrier permeation Drug Discov. Today 8 2003 927 933
29. P. Ertl, B. Rohde, and P. Selzer Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties J. Med. Chem. 43 2000 3714 3717
30. D.F. Veber, S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45 2002 2615 2623
31. I. Kubo, S. Komatsu, and M. Ochi Molluscicides from the cashew Anacardium-occidentale and their large-scale isolation J. Agr. Food Chem. 34 1986 970 973
32. M.L. Bolognesi, R. Banzi, M. Bartolini, A. Cavalli, A. Tarozzi, V. Andrisano, A. Minarini, M. Rosini, V. Tumiatti, C. Bergamini, R. Fato, G. Lenaz, P. Hrelia, A. Cattaneo, M. Recanatini, and C. Melchiorre Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease J. Med. Chem. 50 2007 4882 4897
33. P. Camps, X. Formosa, D. Munoz-Torrero, J. Petrignet, A. Badia, and M.V. Clos Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors J. Med. Chem. 48 2005 1701 1704
34. E. Nepovimova, E. Uliassi, J. Korabecny, L.E. Pena-Altamira, S. Samez, A. Pesaresi, G.E. Garcia, M. Bartolini, V. Andrisano, C. Bergamini, R. Fato, D. Lamba, M. Roberti, K. Kuca, B. Monti, and M.L. Bolognesi Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-beta aggregation and to exert anticholinesterase and antioxidant effects J. Med. Chem. 57 2014 8576 8589
35. S. Nochi, N. Asakawa, and T. Sato Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020) Biol. Pharm. Bull. 18 1995 1145 1147
36. G.L. Ellman, K.D. Courtney, V. Andres, J. Featherstone, and R.M. Featherstone A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 7 1961 88 95
37. A. Porzoor, B. Alford, H.M. Hugel, D. Grando, J. Caine, and I. Macreadie Anti-amyloidogenic properties of some phenolic compounds Biomolecules 5 2015 505 527
38. E. Viayna, R. Sabate, and D. Munoz-Torrero Dual inhibitors of beta-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates Curr. Top. Med. Chem. 13 2013 1820 1842
39. M. Bartolini, C. Bertucci, M.L. Bolognesi, A. Cavalli, C. Melchiorre, and V. Andrisano Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action Chembiochem. A Eur. J. Chem. Biol. 8 2007 2152 2161
40. L. Di, E.H. Kerns, K. Fan, O.J. McConnell, and G.T. Carter High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 38 2003 223 232
41. M.L. Verdonk, J.C. Cole, M.J. Hartshorn, C.W. Murray, and R.D. Taylor Improved protein-ligand docking using GOLD Proteins 52 2003 609 623
42. O. Korb, T. Stutzle, and T.E. Exner Empirical scoring functions for advanced protein-ligand docking with PLANTS J. Chem. Inf. Model. 49 2009 84 96
43. G. Kryger, I. Silman, and J.L. Sussman Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs Structure 7 1999 297 307
44. J. Cheung, M.J. Rudolph, F. Burshteyn, M.S. Cassidy, E.N. Gary, J. Love, M.C. Franklin, and J.J. Height Structures of human acetylcholinesterase in complex with pharmacologically important ligands J. Med. Chem. 55 2012 10282 10286
45. K. Stierand, P.C. Maass, and M. Rarey Molecular complexes at a glance: automated generation of two-dimensional complex diagrams Bioinformatics 22 2006 1710 1716
46. N.G. Castro, R.S. Costa, L.S.B. Pimentel, A. Danuello, N.C. Romeiro, C. Viegas Jr., E.J. Barreiro, C.A.M. Fraga, V.S. Bolzani, and M.S. Rocha CNS-selective noncompetitive cholinesterase inhibitors derived from the natural piperidine alkaloid (-)-spectaline Eur. J. Pharmacol. 580 2008 339 349
47. H. Naiki, K. Higuchi, K. Nakakuki, and T. Takeda Kinetic analysis of amyloid fibril polymerization in vitro Lab. Investig. 65 1991 104 110
48. L. Di, E.H. Kerns, K. Fan, O.J. McConnell, and G.T. Carter High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 38 2003 223 232
49. K. Sugano, H. Hamada, M. Machida, and H. Ushio High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay J. Biomol. Screen. 6 2001 189 196
50. F. Wohnsland, and B. Faller High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes J. Med. Chem. 44 2001 923 930